CLINICAL EFFECTIVENESS AND SAFETY OF IVABRADINE USE IN PATIENTS WITH UNSTABLE ANGINA AND DIABETES MELLITUS TYPE 2
https://doi.org/10.17650/1818-8338-2011-2-80-85
Abstract
Aim – to estimate the clinical and pharmacological effects of ivabradine in complex treatment of patients with acute coronary syndrome and
diabetes mellitus type 2 (DM 2).
Materials and methods. The study included 36 patients with acute coronary insufficiency (unstable angina) and acute left ventricular failure
(Killip class I–III) during concomitant type 2 diabetes.
Results. Prescribing ivabradine in treatment of unstable angina pectoris complicated by type 2 diabetes led to decrease in clinical symptoms,
heart rate and reduce in number of myocardial ischemia episodes. Patients treated with ivabradine, showed a significant tendency to increase left ventricular ejection fraction (12.3 %). Mo adverse reactions were recorded, including hypotensive complications.
Conclusion. Ivabradine therapy was characterized by high ischemic and antianginal efficacy, good tolerability, did not lead to the development
of tolerance and was not accompanied by the appearance of withdrawal syndrome.
About the Author
A. I. Kondratiev
Omsk State Medical Academy, Ministry of Health and Social Development of Russia
Municipal City Hospital of Emergency Medical Care № 1, Omsk
Russian Federation
Russian Federation
References
1. Сторожаков Г.И. Дилатационная кардиомиопатия – связь с воспалением. Журнал Сердечная недостаточность 2008;2:91–7.
2. Терещенко С.Н., Косицына И.В., Голубев А.В. Возможность применения ивабрадина в комплексной терапии острого коронарного синдрома. Кардиология 2008;7:10–13.
3. Seccareccia F., Pannozzo F., Dima F. et al; Malattie Cardiovascolari Aterosclerotiche Istituto
4. Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS Project. Am J Public Health 2001;91:1258–63.
5. Di Francesco D. I(f) current inhibitors: properties of drug channel interraction. In: Selective and specific I(f) channel inhibition in cardiology. Fox K., ed. London: Science Press, 2004; p. 1–13.
6. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT-II). Am J Cardiol 1990;66:779–85.
7. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005;10:45–50.
8. Ерофеева С.Б., Манешина О.А., Белоусов Ю.Б. Место ивабрадина – первого If ингибитора избирательного и специфического действия, в лечении сердечно-сосудистых заболеваний. Качественная
9. клиническая практика 2006;1:10–22.
10. Mulder P., Barbie S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674–9.
11. Borer J.S., Fox K., Jaillon P., et al.; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebocontrolled trial. Circulation 2003;107:817–23.
12. Monnet X., Colin P., Ghaleh B., et al. Heart rate reduction during exercise-induced myocardial ischemia and stunning. Eur Heart J
13. ;25:579–86.
14. Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna. Сердце 2004;3(1):5–8.
15. Кремнева Л.В., Шалаев С.В. Гипергликемия у больных острым коронарным синдромом. Атеротромбоз 2009;(1):86–94.
16. Оганов Р.Г., Мамедов М.Н. Национальные клинические рекомендации Всероссийского научного общества кардиологов.
17. М.: Меди ЭКСПО, 2009.
18. Malmberg K., Herlitz J., Hjalmarson A., Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute
19. myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989;10(5):423–8.
20. Gundersen T., Syekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–90.
21. Lowel H., Koenig W., Engel S., et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population – based myocardial infarction register follow-up study. Diabetologia 2000;43:218–26.
22. Kveiborg B., Hermann T.S., Major-Pedersen A., et al. Metoprolol compared to carvedilol deteriorates insulin-stimulated
23. endothelial function in patients with type 2 diabetes – a randomized study. Cardiovasc Diabetol 2010;9:21.
24. Fox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction
25. (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;10:70–8.
Review
For citations:
Kondratiev A.I. CLINICAL EFFECTIVENESS AND SAFETY OF IVABRADINE USE IN PATIENTS WITH UNSTABLE ANGINA AND DIABETES MELLITUS TYPE 2. The Clinician. 2011;5(2):80-85. (In Russ.) https://doi.org/10.17650/1818-8338-2011-2-80-85
Views:
910
Email this article 